常规监测多普勒超声及后续再干预对股浅动脉支架置入术后结果的影响
该单中心回顾性研究纳入2005至2020年间接受股浅动脉支架置入并有超声随访的257例患者,按支架内再狭窄、症状及是否再干预分为5组,主要终点为无截肢生存,次要终点为通畅率;结论认为常规监测超声及对支架内再狭窄的再干预与通畅率和无截肢生存改善相关。
要点
- 支架内再狭窄且无症状但接受再干预者截肢率最低,为13%。
- 支架内再狭窄且有症状但未再干预者结局最差,截肢率达50%。
- 术后双联抗血小板治疗与保肢正相关(HR 0.23,95%CI 0.09-0.58,P=.001)。
核心结论
- 常规监测多普勒超声及对股浅动脉支架置入术后支架内再狭窄的后续再干预与通畅率和无截肢生存改善相关。
- 作者认为支架置入术后应常规行监测超声,若发现支架内再狭窄,无论有无症状均强烈考虑再干预。
研究设计与样本
- 单中心、回顾性研究,纳入2005至2020年间接受股浅动脉支架置入并有多普勒超声随访的患者。
- 共257例患者纳入分析,干预指征为间歇性跛行28%、慢性肢体威胁性缺血72%。
- 按支架内再狭窄与否、有无症状及是否再干预分为5组:ISR+SX+R、ISR+SX+NR、ISR+ASX+R、ISR+ASX+NR、NISR+NR。
- 主要终点为无截肢生存,次要终点为通畅率;采用多因素logistic回归和Cox多因素回归模型识别死亡和监测的预测因素,Kaplan-Meier曲线以log-rank检验进行亚组比较。
主要发现
- 共161例患者(63%)因支架内再狭窄接受再干预。
- 支架内再狭窄且有症状未再干预组(ISR+SX+NR)结局最差,截肢率为50%。
- 支架内再狭窄且无症状但接受再干预组(ISR+ASX+R)截肢率最低,为13%。
- 当前吸烟是通畅率丧失和截肢的预测因素(1.72;95%CI 1.00-2.98;P=.050;3.55;95%CI 1.53-8.25;P=.003)。
- 术后双联抗血小板治疗与保肢正相关(HR 0.23;95%CI 0.09-0.58;P=.001);糖尿病(HR 2.61;95%CI 1.21-6.01;P=.019)、支架闭塞(HR 17.0;95%CI 5.93-63.1;P<.001)和慢性肢体威胁性缺血表现(HR 4.31;95%CI 1.86-11.7;P=.002)与保肢负相关。
关键数值与推荐
- 作者结论认为常规监测多普勒超声及对支架内再狭窄的后续再干预与通畅率和无截肢生存改善相关。
- 作者认为支架置入术后应常规行监测超声,若发现支架内再狭窄,无论有无症状均强烈考虑再干预。
临床怎么用
- 作者认为股浅动脉支架置入术后应常规行监测多普勒超声。
- 作者认为若监测超声发现支架内再狭窄,无论患者有无症状均强烈考虑再干预。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Superficial femoral artery (SFA) stenting is a common treatment for peripheral artery disease. It is effective in the short term; however, in-stent restenosis (ISR) limits long-term success. Surveillance with duplex ultrasound (DUS) can identify patients who develop ISR leading to early reintervention, but data to support this practice is sparce. The purpose of this study was to evaluate whether surveillance and subsequent reintervention improves outcomes in patients with SFA stents. METHODS: A single-center, retrospective study was performed with patients undergoing SFA stenting between 2005 and 2020 who had a follow-up with DUS. Five groups were identified based on the presence of ISR on DUS (ISR vs no ISR [NISR]), recurrence of symptoms (symptomatic [SX] vs asymptomatic [ASX]), and if any reintervention was performed (reintervention [R] vs no reintervention [NR]): (1) ISR+SX+R; (2) ISR+SX+NR; (3) ISR+ASX+R; (4) ISR+ASX+NR; and (5) NISR+NR. The primary endpoint was amputation-free survival, and the secondary endpoint was patency. Predictors of mortality and surveillance were identified by multivariable logistic regressions and Cox multivariate regression models. Survival curves were presented as Kaplan-Meier plots using log-rank test for subgroup comparison. RESULTS: Two hundred fifty-seven patients were included in the analysis. The indication for intervention was claudication in 28% and chronic limb-threatening ischemia in 72%. A total of 161 patients (63%) underwent reintervention for ISR. Of patients who had restenosis on DUS, those who were symptomatic and did not undergo reintervention (ISR+SX+NR) did the worst, with 50% amputation rate. In contrast, those who were asymptomatic but did undergo reintervention (ISR+ASX+R) had the lowest amputation rate of 13%. Active smoking was a predictor of both loss of patency and amputation (1.72; 95% confidence interval [CI], 1.00-2.98; P = .050; 3.55; 95% CI, 1.53-8.25; P = .003). Post procedure dual antiplatelet therapy had a positive association with limb salvage (hazard ratio [HR], 0.23; 95% CI, 0.09-0.58; P = .001), whereas diabetes (HR, 2.61; 95% CI, 1.21-6.01; P = .019), stent occlusion (HR, 17.0; 95% CI, 5.93-63.1; P < .001), and chronic limb-threatening ischemia presentations (HR, 4.31; 95% CI, 1.86-11.7; P=.002) were negatively associated with limb salvage. CONCLUSIONS: Routine surveillance DUS and subsequent reintervention on ISR after SFA stenting is associated with improved patency and amputation-free survival. Surveillance DUS should be routine for patients after stenting, with reintervention strongly considered if ISR is identified for both symptomatic and asymptomatic.
引用
- Shih M, Pizano A, Solano A, et al. Impact of routine surveillance duplex ultrasound and subsequent reintervention after superficial femoral artery stenting. J Vasc Surg. 2023. PMID: 37704092. doi:10.1016/j.jvs.2023.09.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。